Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 4, 2012, Pages 1010-1016

  Gomez, Daniel R ^a   Tucker, Susan L ^a   Martel, Mary K ^a   Mohan, Radhe ^a   Balter, Peter A ^a   Guerra, Jose Luis Lopez ^a,b   Liu, Hongmei ^a   Komaki, Ritsuko ^a   Cox, James D ^a   Liao, Zhongxing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Chemotherapy; DVH modeling; Esophagitis; Intensity modulated radiation therapy

Indexed keywords

BIOLOGICAL ORGANS; CHEMORADIOTHERAPY; CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; CONFORMAL MAPPING; DISEASES; PATIENT TREATMENT; PROTON BEAM THERAPY; PROTON BEAMS; RISK PERCEPTION;

CONCURRENT CHEMOTHERAPY; DOSE-VOLUME HISTOGRAMS; ESOPHAGITIS; FRACTIONAL EFFECTIVE DOSE; INTENSITY MODULATED RADIATION THERAPY; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY;

RADIOTHERAPY;

CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ADULT; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; DOSE RESPONSE; DOSE VOLUME HISTOGRAM; ESOPHAGITIS; FEMALE; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; AGED; ARTICLE; INDUCTION CHEMOTHERAPY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; ESOPHAGITIS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROTON THERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84872037066     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.071     Document Type: Conference Paper

References (16)

1. Werner-Wasik M, Yorke E, Deasy J, et al. Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys 2010; 76: S86-S93.
2. Wei X, Liu HH, Tucker SL, et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 100-107.
3. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non small cell lung cancer. Cancer 2011; 117: 3004-3013.
4. Cancer Therapy Evaluation Program: Common terminology criteria for adverse events, version 3. Bethesda, MD. 2003. Available at http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed July 15th 2012.
5. Tucker SL, Dong L, Bosch WR, et al. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys 2010; 78: 1253-1260.
6. Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 2006; 66: 11-19.
7. Mohan R, Mageras GS, Baldwin B, et al. Clinically relevant optimization of 3-D conformal treatments. Med Phys 1992; 19: 933-944.
8. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001; 57: 120-125.
9. Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria. Available at: http://www.rtog.org/ResearchAssociates/ AdverseEventReporting, 2011. Accessed Augsut 10, 2012.
10. Bijl HP, van Luijk P, Coppes RP, et al. Influence of adjacent low-dose fields on tolerance to high doses of protons in rat cervical spinal cord. Int J Radiat Oncol Biol Phys 2006; 64: 1204-1210.
11. Bradley JD, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010; 77: 367-372.
12. Schild SE, McGinnis WL, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unre-sectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1106-1111.
13. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76: S10-S19.
14. Werner-Wasik M, Paulus R, Curran WJ Jr, et al. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the Radiation Therapy Oncology Group (RTOG) database. Clin Lung Cancer. 12: 245-251.
15. Shi A, Zhu G, Yu R, et al. [A randomized phase I/II trial to compare weekly usage with triple weekly usage of paclitaxel in concurrent radiochemotherapy for patients with locally advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2011; 14: 227-232.
16. McCurdy M, McAleer MF, Wei W, et al. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys 2010; 76: 816-823.